Riskpilot← Back to searchSign inGet full accessASTELLAS PHARMA NUF
NUFActiveOrg 968090364C. J. Hambros Plass 2, 0164 OsloActivities of agents involved in the wholesale of other particular products · NACE 4618Est. 19955 employeeswww.astellas.com
Revenue 2025
NOK 34,5M
+18387% vs 2024
EBITDA margin
4.0%
+23038% vs 2024
Equity ratio
—
Financial strength
Net profit 2025
NOK 981K
+21852% vs 2024
| Revenue | NOK 34,5M | +18387% |
| EBITDA | NOK 1,4M | +23038% |
| Net profit | NOK 981K | +21852% |
| Total assets | NOK 8,1M | +7909% |
| Equity | NOK 0 | -100% |
| Employees | 5 | — |
Legal name
ASTELLAS PHARMA NUF
Org number
968090364
Legal form
Norskregistrert Utenlandsk Foretak
NACE code
4618 · Activities of agents involved in the wholesale of other particular products
Founded
20. februar 1995
Share capital
—
Employees
5 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-03-31
Financial year
January – December
Signatory rights
Utgår
Address
C. J. Hambros Plass 2, 0164 Oslo
Website
www.astellas.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 43 400 | 0 | 48 660 | 39 183 | 41 297 | 43 867 | 48 372 | 51 717 | 49 035 | 39 613 | 180 837 | 187 | 34 545 |
| Staff expenses | −0 | −0 | −0 | −0 | −0 | −0 | −19 818 | −0 | −29 084 | −21 736 | −22 518 | −23 461 | −25 554 | −27 853 | −26 912 | −23 357 | −17 877 | −15 | −12 604 |
| EBITDA | 0 | 0 | 0 | 0 | 0 | 0 | 1 605 | 0 | 2 085 | 1 548 | 1 504 | 1 587 | 1 966 | 2 001 | 3 497 | 2 111 | 5 224 | 6 | 1 387 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 | −0 | −61 | −0 | −72 | −30 | −19 | −1 | −124 | −162 | −169 | −186 | −126 | −0 | −22 |
| EBIT | 0 | 0 | 0 | 0 | 0 | 0 | 1 544 | 0 | 2 013 | 1 518 | 1 484 | 1 587 | 1 842 | 1 839 | 3 328 | 1 925 | 5 098 | 6 | 1 365 |
| Net financials | 0 | 0 | 0 | 0 | 0 | 0 | 31 | 0 | 14 | 4 | 104 | 101 | 7 | 632 | −974 | −39 | −2 195 | 0 | 213 |
| Profit before tax | 0 | 0 | 0 | 0 | 0 | 0 | 1 574 | 0 | 2 027 | 1 522 | 1 588 | 1 687 | 1 849 | 2 470 | 2 354 | 1 886 | 2 903 | 6 | 1 578 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | 581 | −0 | 829 | 603 | 688 | 724 | 808 | 1 757 | 1 183 | 635 | 822 | −0 | 596 |
| Net profit | 0 | 0 | 0 | 0 | 0 | 0 | 993 | 0 | 1 198 | 919 | 900 | 963 | 1 041 | 714 | 1 170 | 1 252 | 2 081 | 4 | 981 |
| Item | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | — | — | — | — | — | — | 9 476 | — | 13 265 | 8 203 | 8 767 | 10 172 | 11 018 | 11 948 | 14 813 | 33 827 | 112 042 | 101 | 8 071 |
| Equity | — | — | — | — | — | — | 0 | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 35 307 | 25 | 0 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12 | 8 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 9 476 | 0 | 13 265 | 8 203 | 8 767 | 10 172 | 11 007 | 11 940 | 14 813 | 33 827 | 76 735 | 76 | 8 071 |
| Total debt | 0 | 0 | 0 | 0 | 0 | 0 | 9 476 | 0 | 13 265 | 8 203 | 8 767 | 10 172 | 11 018 | 11 948 | 14 813 | 33 827 | 76 735 | 76 | 8 071 |
EBITDA margin
4.0%
This company
15.8%
Market median
-75% vs market
20072025
Equity ratio
0.0%
This company
38.2%
Market median
-100% vs market
20072025
Return on equity
98126700.0%
This company
18.4%
Market median
+533297183% vs market
20072025
Net profit margin
2.8%
This company
8.1%
Market median
-65% vs market
20072025
Asset turnover
4.28×
This company
1.12×
Market median
+282% vs market
20072025
Debt / equity
8070620.00×
This company
0.62×
Market median
-1301712803% vs market
20072025
- Annual report 2025Filed via Brønnøysundsregistrene · Period 2024-04-01 – 2025-03-31
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2023-04-01 – 2024-03-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2022-04-01 – 2023-03-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2021-04-01 – 2022-03-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2020-04-01 – 2021-03-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2019-04-01 – 2020-03-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2018-04-01 – 2019-03-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2017-04-01 – 2018-03-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2016-04-01 – 2017-03-31
- Annual report 2016Filed via Brønnøysundsregistrene · Period 2015-04-01 – 2016-03-31
- Annual report 2015Filed via Brønnøysundsregistrene · Period 2014-04-01 – 2015-03-31
- Annual report 2014Filed via Brønnøysundsregistrene · Period 2014-04-01 – 2014-03-31
- Annual report 2013Filed via Brønnøysundsregistrene · Period 2012-04-01 – 2013-03-31
- Annual report 2012Filed via Brønnøysundsregistrene · Period 2012-01-01 – 2012-12-31
- Annual report 2011Filed via Brønnøysundsregistrene · Period 2011-01-01 – 2011-12-31
- Annual report 2010Filed via Brønnøysundsregistrene · Period 2010-01-01 – 2010-12-31
- Annual report 2009Filed via Brønnøysundsregistrene · Period 2009-01-01 – 2009-12-31
- Annual report 2008Filed via Brønnøysundsregistrene · Period 2008-01-01 – 2008-12-31
- Annual report 2007Filed via Brønnøysundsregistrene · Period 2007-01-01 – 2007-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
MA Chief Executive Officer | Chief Executive Officer | 2025 | — | — |
MA Chief Executive Officer | Chief Executive Officer | 2025 | — | — |
KH Chief Executive Officer | Chief Executive Officer | 2022 | — | — |
AS Contact Person | Contact Person | 2021 | — | — |
PW Chief Executive Officer | Chief Executive Officer | 2015 | — | — |
No data on file.
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of ASTELLAS PHARMA NUF also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Morten Auscher | Chief Executive Officer | 0 companies |
| Mark Andree Dekker | Chief Executive Officer | 0 companies |
| Karl Håkan Lennart Widen | Chief Executive Officer | 0 companies |
| Anniken Strid | Contact Person | 0 companies |
| Paul Waaler | Chief Executive Officer | 0 companies |